Your browser doesn't support javascript.
loading
Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.
Byrn, Randal A; Jones, Steven M; Bennett, Hamilton B; Bral, Chris; Clark, Michael P; Jacobs, Marc D; Kwong, Ann D; Ledeboer, Mark W; Leeman, Joshua R; McNeil, Colleen F; Murcko, Mark A; Nezami, Azin; Perola, Emanuele; Rijnbrand, Rene; Saxena, Kumkum; Tsai, Alice W; Zhou, Yi; Charifson, Paul S.
Afiliação
  • Byrn RA; Department of Infectious Diseases, Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.
  • Jones SM; Department of Infectious Diseases, Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.
  • Bennett HB; Department of Infectious Diseases, Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.
  • Bral C; Department of Drug Safety Evaluation, Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.
  • Clark MP; Department of Chemistry, Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.
  • Jacobs MD; Department of Protein Sciences, Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.
  • Kwong AD; InnovaTID Pharmaceuticals, Cambridge, Massachusetts, USA.
  • Ledeboer MW; Department of Chemistry, Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.
  • Leeman JR; Department of Infectious Diseases, Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.
  • McNeil CF; Department of Infectious Diseases, Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.
  • Murcko MA; Disruptive Biomedical, LLC, Holliston, Massachusetts, USA.
  • Nezami A; Department of Protein Sciences, Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.
  • Perola E; Department of Computational Sciences, Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.
  • Rijnbrand R; Department of Infectious Diseases, Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.
  • Saxena K; Department of Protein Sciences, Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.
  • Tsai AW; Department of Drug Metabolism and Pharmacokinetics, Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.
  • Zhou Y; Department of Infectious Diseases, Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.
  • Charifson PS; Department of Chemistry, Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA paul_charifson@vrtx.com.
Antimicrob Agents Chemother ; 59(3): 1569-82, 2015 Mar.
Article em En | MEDLINE | ID: mdl-25547360
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2015 Tipo de documento: Article